Американское общество гирудотерапии

Hirudin-based anticoagulant strategies for patients with suspected heparin-induced thrombocytopenia undergoing percutaneous coronary interventions and bypass grafting

Review published in Journal of Thrombosis and Thrombolysis (2000)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewРазработка лекарственных препаратовКлинические исследованияBecker RC · Journal of Thrombosis and Thrombolysis, 2000

Abstract

Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug reaction that is associated with thrombotic events of the venous and arterial circulatory systems stemming from an intense and well-characterized prothrombotic triad of platelet activation, coagulation cascade stimulation and vascular endothelial cell injury. Although heparin (or other sulfated mucopolysaccharide compound) cessation represents a vital first step in management, patients remain susceptible to life-threatening thrombosis for up to several weeks, providing a strong rationale for a 'proactive approach' to care that includes prompt initiation of an alternative anticoagulant strategy throughout the high-risk period. The importance of alternative options for anticoagulation is most evident in clinical situations wherein treatment is a recognized standard of care and prerequisite for an optimal outcome. The following review highlights the use of recombinant hirudin (lepirudin) among patients with suspected HIT requiring precutaneous coronary interventions (PCI) and coronary arterial bypass grafting.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAngioplasty, Balloon, CoronaryAnticoagulantsAntithrombinsBlood Coagulation TestsCoronary Artery BypassHeparinHirudin TherapyHirudinsHumansRecombinant ProteinsRiskThrombocytopenia

Резюме

Review of recombinant hirudin (lepirudin) anticoagulant strategies for HIT-suspect patients requiring PCI or coronary artery bypass grafting; emphasizes proactive alternative anticoagulation throughout the multi-week prothrombotic window after heparin cessation.

Почему это важно для гирудотерапии

This review focuses on recombinant hirudin (lepirudin) as an alternative anticoagulant for patients with suspected heparin-induced thrombocytopenia (HIT) who require percutaneous coronary intervention (PCI) or coronary artery bypass grafting. It discusses the rationale for prompt initiation of a non-heparin anticoagulant during the high-risk prothrombotic period and practical considerations for hirudin-based strategies in these procedural settings. This is relevant to hirudotherapy as it addresses clinical use of a hirudin-based anticoagulation strategy. However, this is a review with no new primary data, and the abstract does not address the current market availability of lepirudin or provide clinical outcome data.

Цитирование

Hirudin-based anticoagulant strategies for patients with suspected heparin-induced thrombocytopenia undergoing percutaneous coronary interventions and bypass grafting.

Becker RC · Journal of Thrombosis and Thrombolysis, 2000

Связанный клинический контекст

Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: June 18, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.